Lisata Therapeutics, Inc. (LSTA)
| Market Cap | 28.90M +59.7% |
| Revenue (ttm) | 170,000 -83.0% |
| Net Income | -16.35M |
| EPS | -1.86 |
| Shares Out | 9.03M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 69,508 |
| Open | 3.170 |
| Previous Close | 3.140 |
| Day's Range | 3.130 - 3.230 |
| 52-Week Range | 1.810 - 5.070 |
| Beta | 0.81 |
| Analysts | Hold |
| Price Target | 4.00 (+25.0%) |
| Earnings Date | May 11, 2026 |
About LSTA
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. The company was incorporated in 1980 and is headq... [Read more]
Financial Performance
In 2025, Lisata Therapeutics's revenue was $170,000, a decrease of -83.00% compared to the previous year's $1.00 million. Losses were -$16.59 million, -17.01% less than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for LSTA stock is "Hold." The 12-month stock price target is $4.0, which is an increase of 25.00% from the latest price.
News
Lisata Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded Lisata Therapeutics (LSTA) to Neutral from Buy without a price target Risk of the Kuva Labs takeover deal not closing has increased, the analyst tells investors in…
Lisata Therapeutics Quarterly report: Q1 2026
Lisata Therapeutics has published its Q1 2026 quarterly earnings report on May 11, 2026.
Halper Sadeh LLC is Investigating Whether SILA and LSTA are Obtaining Fair Deals for their Shareholders
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
Lisata Therapeutics Annual report: Q4 2025
Lisata Therapeutics has published its Q4 2025 annual report on March 12, 2026.
Lisata Therapeutics to be acquired by Kuva Labs for $5 per share cash plus CVR
Lisata Therapeutics (LSTA) announced that it has entered into a definitive agreement to be acquired by Kuva Labs, a privately-held company. Under the terms of the merger agreement, Kuva will…
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
Each Lisata stockholder to receive $5.00 per share in cash payable at closing plus one contingent value right for a potential additional cash payment of $1.00 per share
Lisata Therapeutics announces mutual termination of license agreement with Qilu
Lisata Therapeutics (LSTA) has mutually terminated the February 2021 Exclusive License and Collaboration Agreement with Qilu Pharmaceutical. The original agreement, negotiated and implemented with CEN...
Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide
Lisata regains full development rights to certepetide in the Greater China Region Lisata regains full development rights to certepetide in the Greater China Region
Lisata Therapeutics downgraded to Hold from Buy at Brookline
Brookline analyst Kemp Dolliver downgraded Lisata Therapeutics (LSTA) to Hold from Buy after the company entered into a binding term sheet to be acquired by Kuva Labs for $4.00 per…
Lisata Therapeutics to be acquired by Kuva Labs for $4.00 per share
Lisata Therapeutics (LSTA) entered into a binding term sheet to be acquired by Kuva Labs. Pursuant to the terms and conditions of the term sheet, Kuva and Lisata agreed to…
Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer
Stockholders to also receive two contingent value rights valued at $1 per share, each entitled to be received upon the achievement of certain milestones Offer represents an approximate 85% premium ove...
Lisata Therapeutics Earnings Call Transcript: Q3 2025
Q3 2025 saw reduced expenses and net loss, with $19M in cash projected to last into Q1 2027. Certepetide advanced across multiple cancer trials, showing positive efficacy and safety signals, while new partnerships and a key patent strengthened the pipeline.
Lisata Therapeutics Quarterly report: Q3 2025
Lisata Therapeutics has published its Q3 2025 quarterly earnings report on November 6, 2025.
Lisata Therapeutics Earnings release: Q3 2025
Lisata Therapeutics released its Q3 2025 earnings on November 6, 2025, summarizing the period's financial results.
Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Data rich period continues to support certepetide's broad applicability and effectiveness Catalent enters into global license agreement for the use of certepetide as part of their SMARTag® Antibody-Dr...
Lisata Therapeutics Slides: Corporate Presentation
Lisata Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on November 6, 2025.
Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year'
BASKING RIDGE, N.J. , Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies fo...
Lisata Therapeutics highlights iRGD cyclic peptide product candidate data
Lisata Therapeutics (LSTA) highlighted preclinical data as announced by Lisata’s licensing partner, Catalent, at the 16th Annual World ADC San Diego Conference, held November 3-6. Catalent’s presentat...
Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent
BASKING RIDGE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for...
Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025
BASKING RIDGE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for...
Lisata Therapeutics Slides: Corporate Presentation
Lisata Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on October 21, 2025.
Lisata Therapeutics Transcript: LD Micro Main Event XIX Investor Conference
A novel peptide adjuvant is showing significant survival and response improvements in solid tumor cancers, especially metastatic pancreatic cancer, with broad compatibility and no added toxicity. Multiple strategic partnerships, regulatory designations, and a strong financial position support ongoing and future clinical milestones.
Lisata Therapeutics to Present at LD Micro Main Event XIX
Basking Ridge, New Jersey--(Newsfile Corp. - October 13, 2025) - Lisata Therapeutics, Inc. (NASDAQ: LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative th...
Lisata Therapeutics, Catalent announce global ADC licensing agreement
Lisata Therapeutics (LSTA) and Catalent announced a global product license agreement that allows Catalent to incorporate Lisata’s certepetide into antibody-drug conjugates, ADC, developed using Catale...
Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement
Catalent gains global rights to evaluate certepetide and its analogs for use as SMARTag® payloads across multiple ADCs designed to address difficult-to-treat diseases